DKK3 emerged as putative tumor suppressor, as suggested by other studies before.[86, 87] In contrast, the suppression of stromal DKK3, either genetically‐ or antibody‐mediated, inhibits progression of Trp53−/− pancreatic cancers and prolongs survival.[75] On the other hand, DKK3 overexpression sensitizes toward gemcitabine treatment.[88] Thus, DKK3 may act either as a friend or as a foe, depending on the target tissue. This evidence concerns the gene DKK3 and neoplasm.